The helical cytokine interleukin-6 (IL-6) assembles a multiprotein receptor complex. The starting event in the activation of intracellular signaling is the binding of the IL-6/IL-6R␣ subcomplex to two gp130 chains. The homodimerization of gp130 is triggered by two distinct and independent regions of IL-6 called sites 2 and 3. Several IL-6 antagonists have been obtained that affect signaling, but not IL-6⅐IL-6R␣ subcomplex formation. In this paper, we analyze in detail the impact of these antagonists on gp130 binding and dimerization and show that each signaling variant affects gp130 dimerization in vitro and that biological activity on cells decreases in precise parallel to the decrease in gp130 dimerization in vitro. All IL-6 antagonists can be classified into two groups, mapping at either site 2 or 3 in correspondence to their mode of interaction with gp130. We found that site 3 is a large region, which includes residues at the beginning of helix D spatially flanked by residues in the putative AB loop and located at one extremity of the cytokine 4-helix bundle. Interestingly, in leukemia inhibitory factor, another cytokine that signals through gp130, site 3, is topologically conserved but has evolved to bind leukemia inhibitory factor receptor.
The helical cytokine interleukin-6 (IL-6) assembles a multiprotein receptor complex. The starting event in the activation of intracellular signaling is the binding of the IL-6/IL-6R␣ subcomplex to two gp130 chains. The homodimerization of gp130 is triggered by two distinct and independent regions of IL-6 called sites 2 and 3. Several IL-6 antagonists have been obtained that affect signaling, but not IL-6⅐IL-6R␣ subcomplex formation. In this paper, we analyze in detail the impact of these antagonists on gp130 binding and dimerization and show that each signaling variant affects gp130 dimerization in vitro and that biological activity on cells decreases in precise parallel to the decrease in gp130 dimerization in vitro. All IL-6 antagonists can be classified into two groups, mapping at either site 2 or 3 in correspondence to their mode of interaction with gp130. We found that site 3 is a large region, which includes residues at the beginning of helix D spatially flanked by residues in the putative AB loop and located at one extremity of the cytokine 4-helix bundle. Interestingly, in leukemia inhibitory factor, another cytokine that signals through gp130, site 3, is topologically conserved but has evolved to bind leukemia inhibitory factor receptor.
In most instances, growth factors and cytokines drive the sequential assembly of multiprotein receptor complexes (1, 2) . A group of cytokines, constituted by interleukin-6 (IL-6), 1 interleukin-11 (IL-11), oncostatin M, ciliary neurotrophic factor (CNTF), and leukemia inhibitory factor (LIF), received considerable attention during the last few years due to the peculiar properties of their complex receptor system. All of these cytokines assemble multisubunit receptor complexes, which contain both cytokine-specific receptor subunits and common signaling receptor chains (3, 4) . Binding to the former (called ␣ receptor) does not directly contribute to the activation of intracellular signaling but is required to trap the cytokine in a form that enables the additional receptor chains to be recruited. Such common signaling receptors, namely gp130 and/or LIFR, are required to activate intracytoplasmic events (5, 6) . The gp130 subunit is always present in these receptor complexes, either in the form of a homodimer, as in the case of IL-6, or as a heterodimer with LIFR, in the case of CNTF and LIF (4) . The constant presence of gp130 thus provides the explanation for the partial functional redundancy of these polypeptide hormones (4) .
Recent studies have provided insight into how IL-6 interacts with its two receptors, the IL-6 receptor ␣ (IL-6R␣) and gp130, respectively. All gp130 signaling cytokines were predicted to fold as a bundle of four ␣-helices, sharing the same structural properties observed for growth hormone (GH) (7) (8) (9) , prediction recently confirmed with the x-ray crystal structure determination of LIF and CNTF (10, 11) . Although no three-dimensional structure has as yet been obtained, the receptor chains of the IL-6 family have all been shown to contain a conserved 220-amino acid-long region called the cytokine binding domain, which is responsible for binding the cytokine and is predicted to fold as a tandem repeat of immunoglobulin-like ␤-barrels, like the GH receptor (GHbp) (9, 12) . Starting from these considerations, IL-6 interaction with one IL-6R␣ and one gp130 chain has been postulated by molecular modeling studies (13) (14) (15) (16) as being similar to the binding of GH to the cytokine binding domains of its two receptor chains (9) . Mutagenesis of both IL-6 and IL-6R␣ and in vitro binding studies confirmed these predictions and allowed the identification of two regions in IL-6 (sites 1 and 2) responsible for binding, respectively, to IL-6R␣ and gp130 (formation of a trimer), whose location on the IL-6 surface corresponds to the one of the functionally equivalent sites 1 and 2 on GH (13) (14) (15) (16) .
The IL-6 receptor assembly is further complicated by the fact that the fully assembled complex is a hexamer composed of two IL-6, two IL-6R␣, and two gp130 molecules (17, 18) . In the hexamer, two "GH-like" IL-6⅐IL-6R␣⅐gp130 trimers flank each other with inverted orientations, and the hexamer is held together by multiple protein-protein contacts, only a few of which have been identified by site-directed mutagenesis (18) . Evidence has been provided that, among these additional contacts, another independent and topologically distinct gp130 binding site exists on IL-6. This site, called site 3, encompasses residues 153-163 (19) . We used site 2, site 3, and site 2/3 mutants to prove that two gp130 molecules associate to the IL-6⅐IL-6R␣ subcomplex with two topologically distinct orientations, which can be identified through suitable in vitro receptor binding and immunoprecipitation assays (18) .
Recently, another IL-6 region, called 2a, which spans residues Thr 43 -Glu
55
, has been found to take part in signaling (20) . In this paper, we provide evidence that region 2a belongs to site 3 and contacts the same gp130 chain as the previously identified 157-162 region. This finding is well in agreement with our model of IL-6 three-dimensional structure. Site 3 is therefore defined as a composite gp130 binding site, and we discuss its functional and structural equivalence with a topologically conserved gp130 or LIFR binding site present in other cytokines of the same family.
MATERIALS AND METHODS

IL-6
Modeling-Construction of the IL-6 model has already been described (14) . For the structural comparison shown in Fig. 6 Generation and Expression of Substitution Mutants-Construction of mutants DFRD, 157/160, and DFRD-157/160 has already been described (15, 18) . Mutant 2a was constructed using plasmid pHen⌬hIL-6 (14), a derivative of pHEN1 (21) . The mutant was constructed by polymerase chain reaction using the primers H9 (22) , hybridizing downstream to the natural XbaI restriction site, and IL-6/2a (5Ј-CAGCCTTAAGAAGGAGCTGTGTAACGGTAACTCTGACTGTATG-AACAACGACGACGCACTGGCAGAAAACAACCTG-3Ј) containing the BfrII restriction site. Amplified fragments were cut with BfrII and XbaI and ligated into the recipient pHen⌬hIL-6 cut with the same enzymes. The mutant cDNA was then subcloned into Escherichia coli expression vector pT7.7 (23) . The mutation 2a was also subcloned into pT7.7 plasmid already containing mutations 157/160 (18) to generate mutant 157/160 -2a.
The mutant DFRD-157/160 -2a was constructed directly using pT7.7 plasmid by polymerase chain reaction. The same primer IL-6/2a was used together with the primer H5 (22) containing the XhoI restriction site. Amplified fragments were cut with BfrII and XhoI and ligated into the recipient pT7.7 DFRD-157/160 (18) cut with the same enzymes. To obtain the mutant IL-6 DFRD-2a, wild-type IL-6 fragment HindIII/ClaI from clone hyb2 (22) was subcloned into the recipient vector pT7.7 DFRD-157/160 -2a, cut with the same enzymes, to remove mutations 157/160. The identity of all mutants was verified by sequence analysis (24) over the entire polymerase chain reaction amplified region.
The corresponding mutant proteins were produced in large amounts and purified as described (25) .
In Vitro Receptor Binding Assays-In vitro binding assays to sIL-6R␣ were performed as described (14) .
Bioassays-Transcriptional activation of the C-reactive protein gene promoter in the human Hep3B hepatoma cell line was determined and quantified as described (26) . Secreted alkaline phosphatase activity in the supernatant of transfected cells was assayed with a colorimetric reaction using a substrate p-nitrophenylphosphate (26) . The A 405 of the reaction mixture was recorded with a Bio-Rad model 450 automatic plate reader.
Immmunoprecipitations-Expression and labeling of soluble receptors and immunoprecipitation experiments were performed as described previously (18) .
RESULTS
IL-6 Regions 43-55 (2a) and 157-160 Are Predicted to Form a Composite gp130
Binding Site-We have previously identified two distinct areas of the IL-6 surface (called site 2 and site 3), which bind two gp130 subunits with different orientations (18) . Site 2 comprises residues Tyr 31 and Gly 35 in the putative helix A and residues Ser 118 and Val 121 in the putative helix C (14, 15); the four-amino acid substitution mutant DFRD (Y31D/ G35F/S118R/V121D) does not bind gp130 at site 2 and fails to homodimerize gp130; this is in line with its lack of biological activity. Site 3 comprises residues Trp 157 , Asp
160
, and Thr 162 at the beginning of the D helix consistent with the finding that both the double substitution mutant W157R/D160R and the single T162D variant have a strongly decreased, albeit not abolished, gp130 binding at site 3 but not at site 2. Combination of the site 2 and site 3 mutations accordingly results in the almost complete loss of gp130 binding in vitro.
Recently, a third region was shown to be involved in binding to gp130 (20) : substitution of the human IL-6 residues Thr 43 -Glu 55 with the corresponding mouse residues (T43L, K46G, S47N, N48S, M49E, E51M, S52N, S53N, K54D, E55D) gave rise to the IL-6 chimera 2a with reduced biological activity on human IL-6 responsive cell lines. Chimera 2a showed selective impairment of in vitro binding to gp130 but not to IL-6R␣ (20) .
We examined the location of these three functional regions in the IL-6 three-dimensional model (14) . While it is evident that region 2a is in the proximity of the beginning of helix D, where site 3 residues Trp 157 and Asp 160 are situated, site 2 residues are clearly separated from both ( Fig. 1 Table I contains a list of the various IL-6 mutant proteins tested in this study. To generate a complete set of variants of all possible combinations of site 2 (DFRD), site 3 (157/160) and 2a substitutions were generated at the cDNA level, and the corresponding proteins were expressed in E. coli as described under "Materials and Methods." All of the mutants showed levels of expression equivalent to wild-type IL-6 (data not shown).
We also measured in vitro binding of the cytokine variants to soluble IL-6R␣, which requires proper folding of the protein; Table I reports the receptor binding activity for each mutant as determined by enzyme-linked immunosorbent assay (14) . Although some of the combinatorial mutants bind IL-6R␣ less efficiently than wt IL-6 (especially DFRD-2a and DFRD-157/ 160 -2a), as expected receptor binding is never affected more than 2-fold, since none of the individual substitutions maps in the site of interaction of IL-6 with IL-6R␣ (site 1). We conclude that although these IL-6 variants carry the simultaneous substitution of several IL-6 residues (up to 16), none of them is unfolded or destabilized to the point that they unfold under in vitro binding conditions. Next, we measured the binding of the various mutants to baculovirus-produced sgp130. In a first assay, Sepharose beads coated with anti-Myc monoclonal antibody were incubated with a Myc-tagged preparation of sIL-6R␣ and then used to coimmunoprecipitate labeled sgp130 in the presence of increasing concentrations of wild-type or mutant IL-6 molecules. In this assay, wild-type IL-6 was shown to bind gp130 at either site 2 or 3 (18) (see also scheme in Fig. 2A) , and site 2 and 3 mutants can immunoprecipitate gp130 efficiently. The results are shown in Fig. 2B .
Mutant 2a did not show any significant loss in gp130 binding (Fig. 2B, lanes 23-25) , behaving therefore in this assay like the site 2 mutant DFRD and the site 3 mutant 157/160 (Fig. 2B,  lanes 17-22) . Combination of the site 2 DFRD with the site 3 157/160 strongly impairs gp130 binding (Fig. 2B , compare lane 8 with lanes 17 and 20) because both sites are simultaneously altered (18) . Interestingly, a combination of 2a with either site 2 DFRD or site 3 157/160 gives rise to strikingly different behaviors; in the first case (Fig. 2B, lanes 14 -16) , binding to gp130 is almost completely lost, and in the second case (Fig. 2B,  lanes 11-13) , this interaction is not affected. These results are suggestive that region 2a is indeed involved in gp130 binding, since its alteration is synergistic to a site 2 mutation. The parallel behavior of DFRD-2a and DFRD-157/160 indicates that 2a and 157/160 bind the same gp130 molecule; the lower signal obtained with DFRD-2a as compared to DFRD-157/160 mutant can probably be attributed to the higher number of amino acid substitutions present in the former. Evidence that the 2a substitution is not synergistic with a site 3 mutation further reinforces the idea that it normally interacts with the gp130 chain that binds site 3. Finally, combination of DFRD-2a with 157/160 gives a pattern that cannot be distinguished from that of DFRD-2a (Fig. 2B, lanes 5-7) .
An independent confirmation of the previous findings comes from a second series of immunoprecipitations in which we used the mouse anti-human IL-6 monoclonal antibody mAb 16, which inhibits IL-6 bioactivity by interacting with site 3 residues between Gln 154 and Thr 162 (27) . mAb 16 inhibits gp130 homodimerization but leaves wild-type IL-6 free to interact with gp130 only via site 2 (18) (see also scheme in Fig. 3A) . Only DFRD, 2a, and DFRD-2a were tested because in the other variants, substitutions at residues 157/160 destroy binding to mAb 16 . The results are shown in Fig. 3B . As expected, all molecules efficiently co-immunoprecipitate IL-6R␣. However, only the DFRD but not the 2a substitutions blocks gp130 coimmunoprecipitation through site 2. Therefore, it can be concluded that region 2a is not responsible for the binding of gp130 to site 2.
Region 2a Cooperates with 157/160 in Promoting gp130 Dimerization and Biological Activity on Cells-In the previous section, we showed that mutant 157/160 -2a generates a pattern of immunoprecipitation identical to that of the parent mutants and suggested that its ability to bind gp130 via site 2 is unaltered. If these two groups of substitutions are directed toward the same gp130 chain, one can predict that their simultaneous presence would affect binding more than the individual groups of substitutions (157/160 and 2a) and consequently impair gp130 dimerization. All variants were thus tested in the in vitro gp130 dimerization assay. Unlabeled sgp130-Myc was immobilized on protein A-Sepharose beads coated with antiMyc monoclonal antibody; after washing, immunoprecipitations were performed in the presence of unlabeled sIL-6R␣, 35 S-labeled sgp130, and either wt IL-6 or the various IL-6 mutants. In this case, a hexameric receptor assembly is obtained using wild-type IL-6 (18) as outlined in Fig. 4A . The results (Fig. 4B) show that while the capacity of the single 2a and 157/160 mutants to dimerize gp130 is only partially re- , 1 g, and 10 g ) of wt or variant IL-6 as indicated above the lanes. After incubation and washing, the bound material was subjected to polyacrylamide gel electrophoresis analysis. M, molecular weight marker.
TABLE I Receptor binding activity of IL-6 mutants
Binding of IL-6 variants to IL-6R␣ was determined in vitro by enzyme-linked immunosorbent assay as described (14) and compared to that of wild-type recombinant IL-6 (considered as 100%). On average, the standard error was between 4 and 38% of the IL-6R␣ binding value. duced, the effect is strongly reinforced in the double mutant. In addition, since DFRD has already lost gp130 dimerization as previously observed (18) , all its derivatives behave in the same way. The amount of 35 S-labeled sgp130 immunoprecipitated in each lane was quantified by Phosphorimager, and the values obtained were plotted against the amount of cytokine used. The dimerization efficiency of each mutant was calculated as the ratio between the amount of wt IL-6 and the amount of mutant necessary to obtain 10% of wt IL-6 maximal dimerization, and the results are reported in Table II. Dimerization of gp130 on the surface of target cells is required for signaling activation. Therefore, the various capacity of the IL-6 mutants reported in this study to drive gp130 dimerization in vitro should correlate with differences in biological activity. To test this hypothesis, we determined the biological activity of the various mutants in Hep3B human hepatoma cells, where IL-6 enhances transcription from a transfected human C-reactive gene promoter fused to the secreted alkaline phosphatase reporter gene (26) . The results are shown in Fig. 5 . All the mutants that failed to induce gp130 dimerization in vitro showed no detectable biological activity. Mutants 2a and 157/160 showed an approximately 50-fold reduction in bioactivity ( Fig. 5 and Table II) , and neither of them was able to reach the same levels of wt IL-6 maximal stimulation; in line with its decreased dimerization efficiency, the combinatorial variant 157/160 -2a has a further 10-fold reduction in biological activity. The data in Table II indicate that there is a quantitative correlation between the mutants sgp130 in vitro dimerization efficiency and their biological activity on human hepatoma cells.
DISCUSSION
Molecular modeling, site-directed mutagenesis, and in vitro receptor binding assays have synergistically contributed during the last few years to defining the functional and structural determinants of the IL-6 molecule and the mechanism governing the assembly of a multi-subunit receptor complex. This process is mediated by interactions that two IL-6⅐IL-6R␣ subcomplexes establish simultaneously with two gp130 receptor subunits. Selective alterations introduced in IL-6 at sites recognizing one or the other gp130 chain result in the assembly of incomplete receptor complexes because gp130 homodimerization is impaired. As a consequence, the corresponding IL-6 variants are biologically inactive and act as receptor antagonists.
In the present paper, we provide a structural basis for the mode of action of all previously isolated antagonistic amino acid substitutions in IL-6 (14, 15, 20, 27, 28) . Molecular modeling and in vitro gp130 binding allow us to classify these mutants (and the corresponding surface areas on IL-6) into two groups: 1) substitutions in helices A and C affect interaction with a gp130 chain (site 2) that is bound by the IL-6⅐IL-6R␣ subcomplex with the same topology and similar structural determinants as observed in the GH-(GHbp) 2 receptor complex (16, 18) and 2) substitutions at the beginning of helix D and in the initial part of the AB loop both affect binding to another gp130 chain (site 3). Previous studies have demonstrated that mAb 16 interacts with residues located at the beginning of helix D (19, 27) ; in line with this amino acid substitution in this region has the same effect on receptor complex assembly as the binding of mAb16 to IL-6.
The second gp130 binding site is a composite surface area whose structure is difficult to predict accurately since the portion of the molecule corresponding to the beginning of the AB loop often proves very flexible, as observed for other helical cytokines like GH, G-colony-stimulating factor, and CNTF (11, 29, 30) . It cannot be excluded that this flexible part undergoes S-labeled material. After incubation and washing, the bound material was subjected to polyacrylamide gel electrophoresis analysis. structural stabilization upon binding to gp130 and thus indeed requires a receptor chain to assume an ordered "active" conformation. On the other hand, the complexity and flexibility of site 3 may be responsible (and necessary) to adapt to gp130, thus explaining why also multiple substitutions in IL-6 do not completely abolish signaling.
In the known structures of the GH and prolactin helical cytokines complexed with their receptors (9, 30, 31) , the region corresponding to the IL-6 site 3 is not engaged in binding and thus cannot be used as a structural template in comparative modeling studies. The same is true for the recently determined structure of interferon-␥ in complex with its high affinity receptor (32), which differs significantly from the GH-like assembly topology postulated for IL-6. It is therefore impossible to model site 3-gp130 (second chain) contact surfaces as accurately as can be done for site 2-gp130 (first chain) and to predict the contribution of individual IL-6 residues in binding.
The location of residues that when mutated affect site 3 function is shown in detail in Fig. 6A S-labeled sgp130-FLAG (50 l of supernatant) in the presence of cold sIL-6R␣ (500 l of supernatant) and increasing amounts (100 ng, 1 g, and 10 g) of wt or variants of IL-6 as indicated. After incubation and washing, the bound material was subjected to polyacrylamide gel electrophoresis analysis. M, molecular weight marker.
FIG. 5.
Biological activity of wild-type and variant IL-6 on human hepatoma Hep3B cells. Cells were induced in duplicate with increasing amounts of either wt or variants of IL-6, and the transcriptional activation of the C-reactive protein gene promoter linked to the coding region of the gene for the secreted alkaline phosphatase, transfected into Hep3B cells, was determined and quantified as described (26) . Secreted alkaline phosphatase activity in the supernatant of transfected cells was assayed with a colorimetric reaction, which determines changes in the A 405 of the reaction mixture (26) . The horizontal line in the plot represents 10% of wt IL-6 maximal stimulation. How do these findings on IL-6 fit with the structural information available for LIF and CNTF? In the region corresponding to site 3, both molecules share a similar overall spatial configuration, together with some differences in the precise structural conformation and surface topography of the A-B loop and the D-helix. In the absence of mutagenesis data for CNTF in the region of site 3, a comparison is possible only with LIF, where experiments on human-mouse chimeras have identified six residues responsible for the differential binding of human LIF to the human LIFR (33) . Fig. 6B shows the spatial distribution of these residues on the LIF molecule. Interestingly, three residues map in regions similar to IL-6 site 3, namely the initial segment of the AB loop (Glu 56 ) and the beginning of helix D (Ala What emerges from this analysis is that site 3 has evolved as a versatile gp130/LIFR binding site in IL-6 binding gp130, in LIF binding LIFR, and in CNTF, possibly recognizing either receptor chain. In general, the presence of a site 3 can be anticipated for other members of the IL-6 family like IL-11, oncostatin M, and cardiotrophin (all of which use gp130 and/or LIFR as signaling subunit) and for other helical cytokines, such as interleukin-12, which recruit more than two receptor subunits in their signaling competent complexes.
The final aspect of our work is the evidence that in vitro dimerization assay exactly reflects receptor assembly on the surface of target cells. It is hence possible to establish a precise parallel between biological activity of site 2, 3, and 2/3 IL-6 variants in hepatoma cells and their efficiency to dimerize gp130. The sensitivity of this assay could also be adjusted by varying concentrations of cold sIL-6R␣ and wt or mutant cytokine to mimic what happens on cell lines with different sensitivity to IL-6. This type of analysis could provide invaluable information to the study of a wide variety of receptor assemblies. 
